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Abstract
Background: There are very few studies that report the incidence of acute leukemias in children
in Latin America. This work assesses the incidence of acute leukemias, between 1996 and 2000, in
children from 0–14 years old who were attended at the Mexican Social Security Institute in Mexico
City and in children from 0–11 years old in El Salvador.
Methods: Design: Population-based data. Hospitals: In San Salvador, El Salvador, Hospital Nacional
de Niños "Benjamín Bloom", the only center in El Salvador which attends all children, younger than
12 years, with oncologic disease. The Pediatric Hospital and the General Hospital of the Mexican
Social Security Institute in Mexico City, the only centers in Mexico City which attend all those
children with acute leukemia who have a right to this service. Diagnosis: All patients were
diagnosed by bone marrow smear and were divided into acute lymphoid leukemia (ALL), acute
myeloid leukemia (AML), chronic myeloid leukemia (CML), and unspecified leukemias (UL). The
annual incidence rate (AIR) and average annual incidence rate (AAIR) were calculated per million
children. Cases were stratified by age and assigned to one of four age strata: 1) <1 year; 2) 1–4
years; 3) 5–9 years, or 4) 10–14 or 10–11 years, for Mexico City and El Salvador, respectively.
Results: The number of cases was 375 and 238 in El Salvador and Mexico City, respectively. AAIRs
in Mexico City were 44.9, 10.6, 2.5, 0.5, and 58.4 per million children for ALL, AML, CML, UL, and
total leukemias, respectively. The AAIRs in El Salvador could not be calculated because the fourth
age stratum in El Salvador included children only from 0–11 years old. The incidence rates for the
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Salvadoran group of 0–11 year olds were 34.2, 7.1, 0.6, 0.2, and 43.2 per million children for ALL,
AML, CML, UL, and total leukemias, respectively.
Conclusion: Reported AIRs for each age group in El Salvador were similar to those from other
American countries. The AAIR of ALL in Mexico City is one of the highest reported for North
America.
Background
Leukemias are the most frequent type of cancer in child-
hood [1], the incidence of which varies depending on the
area of the world where they are studied [2]. An elevated
frequency of acute leukemias has been reported in popu-
lations of Hispanic origin [3-5]. For example, in Costa
Rica, the highest incidence rate in the world for acute
leukemias has been reported: 56 per million of children
under the age of 15 years [5]. In California and Texas, two
states of the U.S. which have a Hispanic component pre-
dominately of Mexican origin [3], the incidence rates for
ALL and for AL in general have been found to be greater
than those previously reported for Mexico City [6-8].
However, because the studies carried out in Mexico City
have been retrospective, it is possible that a under-register
of the infirmity may have existed in Mexico City. In Flor-
ida, the state with the highest predominance of Hispanics
of Caribbean and Central American origin, the incidence
rate of ALL was higher than that reported for the Cauca-
sian population and similarly elevated to that reported for
Costa Rica. For the Central American country of El Salva-
dor, there is no prior information on the incidence of
acute leukemias.
In developing countries, there are few data on the fre-
quency of leukemias during childhood [5,9] because
these countries have not had the infrastructure required to
keep reliable records. Some international studies have
produced information from some developing countries,
particularly in Latin America [10]; however, this informa-
tion has certain constraints with respect to its validity and
coverage in representing the populations [11-15] Of the
studies carried out in Mexico City, an important increase
in the incidence of ALL, but not of AML, has been
reported. In 1991, an incidence of 22.2 per million of chil-
dren under 15 years of age was reported [6]. From the data
from the Instituto Mexicano del Seguro Social, the Medi-
cal Center having the greatest coverage of the population
in the whole of the country, an incidence rate was
reported of 29.1 per million of children under 15 years of
age who were residents of Mexico City and who had the
right to receive attention from this Institution [7]. Given
the retrospective nature of these studies, it is possible that
there was underestimation of the incidence rate of ALL.
On the other hand, when taken into account that, in the
different states in the U.S. which have a high component
of Hispanics of Mexican origin, the incidence rate of acute
leukemias is the highest in the world, one may consider it
important to perform a prospective population-based
study in Mexico City that would determine if Mexican
children, residing in this City, had an incidence rate simi-
lar to those reported for Texas and California [3].
Prospective records of those children treated for leukemia
was initiated in El Salvador in 1994 and in Mexico City in
1996 [16,17]. In Mexico City, the record was kept in the
hospitals of the Instituto Mexicano del Seguro Social
(IMSS), an institution that attends about 50% of the pop-
ulation inhabiting Mexico City [7]. Because the IMSS
keeps a register of the population that has a right to
receive medical attention at its facilities, the base popula-
tion is known and it is feasible to obtain the incidence rate
for the population under 15 years of age. In El Salvador,
because the record was kept by the Hospital Nacional de
Niños "Benjamín Bloom" (BB), the only center in the
country which attends all children, younger than 12 years
with oncologic disease, data on the population base
which was necessary for calculating the incidence rate was
available. Treatment of children with leukemia is com-
pletely free of charge both in El Salvador and at the IMSS
in Mexico City, thus allowing a greater coverage for chil-
dren with this disease [16,17].
This work presents the incidence of leukemia in children
younger than 12 years, because this is the age range admit-
ted in the BB and data for children younger than 15 is
used for Mexico City. In this report, for purposes of anal-
ysis, the data from 1996–2000 were used, with 1996
being the first year of record keeping in Mexico City and
2000 being the most recent year for data reported from El
Salvador.
Methods
Design
Population-based data.
Hospitals
The Hospital Nacional de Niños "Benjamín Bloom" (BB),
located in San Salvador, capital of El Salvador; is a tertiary
care center and is the only hospital in that country that has
a pediatric hematology-oncology service with pediatric
hematology staff. Being the only domestic reference center
for pediatric oncologic diseases, it is the only hospital to
which children with presumed leukemia diagnosis areBMC Cancer 2005, 5:33 http://www.biomedcentral.com/1471-2407/5/33
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referred for treatment. For this reason and because treat-
ment is completely free of charge [16], no case of pre-
sumed childhood leukemia should be missing from the
records. Children from other countries (Nicaragua, Hon-
duras, etc) were excluded from the numerator.
The hospitals included in the Mexico City study were the
Pediatric Hospital of the Centro Médico Nacional "Siglo
XXI" (HP) and the General Hospital of the Centro Médico
Nacional "La Raza" (HG). Children who were attended in
the pediatric hematology service and who resided in Mex-
ico City were included in both hospitals. There are accu-
rate records on the population that has a right to this
service because the population attended by this institu-
tion in Mexico City is formed by workers whose personal
data are registered. Only those children who were Mexi-
can nationals and whose parents were residents of Mexico
City were included in the numerator.
Diagnosis
Once diagnosed with presumed leukemia, a child was
referred to one of the hospitals where trained staff did a
comprehensive follow-up of the case to either discard or
confirm the diagnosis of leukemia. In the BB, infirmary
staff trained for that activity carried out this work. In all
cases, the diagnosis was confirmed with bone marrow
smear, and histochemical tests (myeloperoxidase, sudan
black B reaction, esterases, periodic acid Schiff (PAS) reac-
tion, and acid phosphatase) were performed to differenti-
ate the types of leukemia. In the cases in El Salvador, the
staff of St. Jude Hospital confirmed some diagnostic tests
[16].
The types of leukemia were divided according to the five-
group morphological classification of the international
classification of childhood cancer. Only four of the types
were found in this study: a) Acute lymphoid leukemia
(ALL) (9820–9827, 9850); b) acute myeloid leukemia
(AML), the preferred terminology instead of "acute nonl-
ymphocytic leukemia" [18] (9840, 9841, 9861, 9864,
9866, 9867, 9891, 9894, 9910); c) chronic myeloid leuke-
mia (CML) (9863, 9868); and e) unspecified leukemias
(UL) (9800–9804) (International Classification of Dis-
ease for Oncology, ICD-O2; 1990) [19]. The codes were
reviewed with the Child-Check program [19] to corrobo-
rate that there were no duplicate records or inconsistent
data. A database was generated to record age, sex, resi-
dency, year of diagnosis, and clinical manifestation of the
patients.
Populations
Because, in El Salvador, only children under the age of 12
are attended at the BB, our analysis was limited to that
cohort, instead of that conventionally used in a study of
this type, i.e., children younger than 15 years [2,10]. The
denominators to calculate the rates were obtained by
every year from the General Direction of Statistics and
Census (Dirección General de Estadística y Censos),
which is the only government source that calculates the
estimates of population in El Salvador. The population
younger than 12 was 1,756,513; 1,764,422; 1,787,064;
1,808,946, and 1,829,146 for the years 1996 to 2000,
respectively. The last available census in El Salvador dates
from 2000.
In Mexico City, the denominators were obtained from the
Coordination of Planning and Medical Information of the
IMSS, which is the only government source that calculates
all the populations with access to medical attention pro-
vided by the IMSS [20]. This information is updated every
year by the IMSS. The recorded population younger than
15 years in Mexico City was 786,754; 832,199; 765,268;
806,043; and 881,887 for the years 1996 to 2000, respec-
tively. The recorded population of children in Mexico City
appeared to fluctuate from year to year because only that
population of workers who are under contract with a
company are entitled to the care provided by the IMSS.
Thus, the denominator reflects the change in the number
of jobs created or lost each year.
Analysis
Annual incidence rates (AIR) were calculated by age
group, sex, and each type of leukemia. Also, the average
annual incidence rate (AAIR) was calculated by sex and
total for the whole study period. These rates were stand-
ardized by age through the direct method with the world
standard population [21], with the AIR and AAIR reported
per million of children under 15 years old. The AAIRs
were calculated by using the total of cases found in the
study period as numerator and the sum of the populations
found in each year of the study as denominator.
Cases were stratified by age and assigned to one of four
age strata: 1) <1 year; 2) 1–4 years; 3) 5–9 years, or 4) 10–
14 or 10–11 years, for Mexico City and El Salvador,
respectively.
Therefore, for El Salvador, it was not possible to calculate
the AAIR accurately for the 0–14 year-old age group. In the
study, an average rate over the whole period and for the 0–
11 year-old age group was calculated. These rates were
standardized by age by direct method and also with the
world standard population.
Results
During the study period, there were 375 children diag-
nosed with leukemia in El Salvador and 238 in Mexico
City. Of total leukemias in El Salvador and in Mexico City,
ALL represented 80.5% and 76.9%; AML, 16.8% andBMC Cancer 2005, 5:33 http://www.biomedcentral.com/1471-2407/5/33
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Table 1: The incidence of leukemia in children aged 0–14 years in Mexico City from 1996 to 2000.
1996 to 2000 Number of cases by year
Sex n AAIR < 1 year 1–4 years 5–9 years 10–14 years 1996 1997 1998 1999 2000
ALL M 103 49.6* 60.2 82.4 49.9 19.5 n 49 33 33 42 26
F 80 40.1* 36.7 45.9 41.8 33.9 AAIR 62.3 39.6 43.1 52.1 29.5
T 183 44.9* 48.8 64.6 45.9 26.6
AML M 13 6.3* 0 10.5 6.9 3.0 n 941 1 71 2
F 30 15.0* 0 16.5 14.4 17.0 AAIR 11.4 4.8 14.4 8.7 13.6
T4 3 1 0 . 6 * 0 1 3 . 4 1 0 . 6 9 . 9
CML M 5 2.4* 8.6 0 1.4 4.5 n 23041
F 5 2.5* 0 5.5 1.4 1.5 AAIR 2.5 3.6 0 5.0 1.1
T 10 2.5* 4.4 2.7 1.4 3.0
UL M 1 0.5* 0 0 1.4 0 n 10010
F1 0 . 5 *0 0 0 1 . 5 AAIR 1.3 0 0 1.2 0
T 2 0.5* 0 0 0.7 0.8
AAIR: Average Annual Incidence Rate
M = male; F = female; T = total; AAIR = average annual incidence rate per million. AML = Acute myeloid leukemia; ALL = Acute Lymphoid 
leukemia; CML: Chronic Myeloid Leukemia; UL = Unspecified leukemias.* Age standardized rate per million children.
Table 2: The incidence of the leukemias in children younger than 12 years in El Salvador from 1996 to 2000.
1996 to 2000 Number of cases by year
Sex n Rate over the 
entire period
< 1 year 1–4 years 5–9 years 10–11 years 1996 1997 1998 1999 2000
ALL M 162 36.1* 4.9 49.6 36.3 20.1 n 54 64 61 60 63
F 140 32.3* 15.1 47.3 23.0 29.7 Rate over the 
entire period
30.7 36.3 34.1 33.2 34.4
T 302 34.2* 9.9 48.4 29.7 24.8
AML M 37 8.1* 0 9.4 9.2 7.2 n 19 12 12 9 11
F 26 6.0* 7.6 9.1 3.4 4.4 Rate over the 
entire period
10.8 6.8 6.7 5.0 6.0
T 63 7.1* 3.7 9.2 6.3 5.8
CML M 3 0.6* 0 0 1.1 1.4 n 00132
F 3 0.6* 0 0 1.1 1.5 Rate over the 
entire period
0 0 0.6 1.7 1.1
T 6 0.6* 0 0 1.1 1.5
UL M 3 0.7* 2.4 1.2 0 0 n 00112
F 1 0.2* 2.5 0 0 0 Rate over the 
entire period
0 0 0.6 0.5 1.1
T 4 0.5* 2.5 0.6 0 0
AAIR: Average Annual Incidence Rate. M = male; F = female; T = total. AML = Acute myeloid leukemia; ALL = Acute Lymphoid leukemia; CML: 
Chronic Myeloid Leukemia UL = Unspecified leukemias.
* Age standardized rate per million children.BMC Cancer 2005, 5:33 http://www.biomedcentral.com/1471-2407/5/33
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18.1%; CML, 1.6% and 4.2%; and UL, 1.1 and 0.8%,
respectively.
The standardized rate by age of all leukemias in both
countries was higher in boys than in girls, with a more
marked male:female ratio in El Salvador than in Mexico
City: 1.18 (46.8 per million children:39.5 per million
children) vs. 1.01 (58.8 per million children:58.1 per mil-
lion children). Whereas standardized rates by age in El
Salvador revealed that all types of leukemias were more
frequent in boys, this was not observed in AML or CML in
Mexico City, where the frequency of both leukemias was
higher for girls than that reported for boys (Tables I and
II).
The low incidence of ALL in youngsters less than 1 year
old found in El Salvador is notable, as is the fact that no
case of AML in this age group was found in Mexico City.
The data for Mexico City, as those for El Salvador, showed
that ALL had a peak between the ages of 1–4 years (Table
1 and 2). It is important to emphasize that, for the chil-
dren in Mexico City, the age group with the highest AIR
after that of the 1–4 year old group was the group of less
than one year of age.
Among the subtypes of AML, the most frequent in Mexico
City was AML M3 (01B9866) with nine cases, giving a fre-
quency of 20.9% and an AAIR of 2.21 per million chil-
dren. It is noteworthy that all these AML M3 cases were
females. Unfortunately, in El Salvador, the frequency of
AML M3 could not be assessed, as the major part of AML
was classified only in the general category 01B9861.
Discussion
Because there are only two important reviews that sum-
marize the high incidence rates of leukemias in children
reported in the world up to 1999 [1,10], it has been very
difficult to obtain reliable data on the incidence of cancer
in children, including leukemias, in developing countries.
In fact, the review of Parkin et al., carried out in 1999, did
not include data from either El Salvador or Mexico City
because there were no reliable data from these areas at the
time (1980 to 1989) at which they performed their study
[10].
There are some issues of the present study that must be
emphasized. In this study, statistics were not performed to
compare the rates in Mexico City with the rates in El Sal-
vador over time, because this was not the aim. The inclu-
sion of the aforementioned institutions helped guarantee
that all children diagnosed with leukemia during the stud-
ied period were included. This is due to the fact that,
because BB is the only hospital in El Salvador that attends
children with leukemia, any child with presumed
leukemia is referred to that institution [16]. Similarly, in
Mexico City, HP and HG are the only hospitals of the
IMSS that attend the children with leukemia whose par-
ents have rights to receive medical services from IMSS
[17].
Even if there had been an under-registration of cases
because some could not be diagnosed (e.g., patients dying
before leukemia diagnosis is confirmed), the incidence
rates in children of 0–11 years old found in El Salvador are
similar to those reported in North America, which range
from 36 to 45 http://seer.cancer.gov/csr/1975_2001/, and
with rates from South and Central America, which range
from 29.0 to 57.9 per million children [10].
In Mexico City, there are various institutions outside the
IMSS system that can attend children with cancer, particu-
larly leukemia. However, such private institutions repre-
sent an economic burden for the family of the patient, in
that the treatment for patients with leukemia lasts several
years, with the possibility of expenses totaling almost
$65,000 USD [22]. Therefore, it is less probable that the
family of a child with leukemia would turn down access
to the free service offered by HP and HG, opting instead
for a costly private institution. For this reason, we think
that cases in Mexico would not be underestimated due to
patients being treated outside the IMSS system.
Mexico is a developing country with a high rate of child
mortality in general. The absence of AML cases in infants
of less than 1 year in Mexico City is notable because this
is the peak age for AML in most developed countries
[1,23], and suggests the probability that children younger
than 1 year with AML die before being diagnosed. In con-
trast to ALL, AML seems to have no worse prognosis in
children younger than 1 year [24,25], indicating that all
children with AML, regardless of age, run the same risk of
not being diagnosed. This increases the possibility of an
apparently different pattern of age of AML onset in Mexico
City. Little can be argued about the delay of diagnosis in
these diseases, due to fast evolution of the disease and
short-term mortality when no prompt management is
provided; thus, acute leukemias are considered as the ref-
erence point for time of diagnosis [26].
As to the validity of measurements, recommended inter-
national morphological criteria were used in this study,
and all measurements were performed by staff highly spe-
cialized in diagnosis and management of children with
leukemia [7,16].
This study did not aim to assess incidence trend over time,
a parameter that is affected by change(s) in diagnostic cri-
teria [27], which were not a variable in this study. Since
the period under study was too short to assess the inci-BMC Cancer 2005, 5:33 http://www.biomedcentral.com/1471-2407/5/33
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dence trend of leukemia, no analysis was done in this
respect. However, this study evidences once again that
choosing only one year to report a disease incidence may
result in an over- or underestimation of the incidence of
that disease [2]. For example, the observed incidence rate
in Mexico City for the year 1996 in this study was much
higher than those in the following years, suggesting that
this might have been a completely random condition.
Although the standardized rates reported in this study
were higher than those previously reported for Mexico
City, the prior studies [6-8,26,28] were retrospective and
therefore are not comparable to the present study. How-
ever, the possibility that the incidence of ALL is increasing,
particularly in Mexico City as reported in these studies,
must be considered [6,8]. This condition has been
observed in various areas of Mexico City [8] and is associ-
ated with the more polluted areas and with farming areas
[6,8].
The elevated incidence of ALL in children of Mexico City
agrees with those found in other reports that show that
ALL are more frequent in populations of Hispanics [3-5].
Table 3 shows that the AAIR of ALL is the highest reported
for the population of Hispanic origin, with the value for
the Hispanic populations of Texas being the highest, fol-
lowed by that for Florida. Note that the majority of His-
panics in Texas are of Mexican origin[4]. The AAIR for ALL
reported by SEER for Hispanics for the period 1992–1998
is very similar to that reported for Mexico City and agrees
with the fact that, of the Hispanic children included in this
report of SEER, 66% come from the Los Angeles register
[29], where the great majority of the Hispanic population
are of Mexican origin [4].
It is noteworthy that the AAIR of the age peak of ALL in
boys in Mexico City is very high (82.4 per million in
boys), an is higher than that reported for Costa Rica (76
per million in boys) and by SEER (76.7 per million in
both sexs) [5,30]. However, the AAIR reported for Hispan-
ics in general in Florida for the 0–4 year-old age group is
87.6 per million, which to our knowledge is the highest
AAIR reported in the literature [4]. This finding is impor-
tant because this peak in age is related with the higher fre-
quency of ALL with the B-cell precursor
immunophenotype. Although such data were not
reported in this study, this immunophenotype is thought
to be more frequent in developed countries [1] and, in
addition, is related with genetic rearrangements such as
TEL/AML1 that occur in the child during the intrauterine
stage [31].
On the other hand, this age peak had been observed in
relation to high socioeconomic status and population
mixing [1]. The mix of urban and rural populations has
been associated with the development of ALL [32,33] and
especially with the cases that occurred in children under
the age of 5 years [1]. Those states in the U.S.A. that have
reported an elevated AAIR for ALL have an elevated level
of immigration. The greater portion of Hispanics that emi-
grate to these zones come from rural regions. Mexico City
has a similar situation, in that it constantly receives an
influx of people from rural zones. Although, in this study,
patients were determined to be residents of Mexico City,
neither the place from which their parents came nor the
length of time that the children resided in Mexico City was
investigated. It will be important to investigate in the
future if the mix between urban and rural populations is
related with the very high incidence of ALL in Mexico City
and in Hispanics in the U.S.A.
Another factor to be considered is the role of pesticides,
whether occupational exposure of parents or exposure of
children in the home. Also, we must not lose sight of the
activities that Hispanic immigrants in the U.S.A. may per-
form, such as those related to the cultivation of crops,
especially in areas of Texas where a higher frequency of
ALL has been reported [34]. In Mexico City, the major
zones with highest incidence rate of ALL are the zones in
the South of the City where a portion of the population
still carries out agricultural activities [8]. In a study carried
out in Mexico City, an important relation was found
between exposure to pesticides and the risk of developing
AL [35]. In an ecological study realized in California, in
Table 3: Comparison of annual age-adjusted rates of lymphoid leukemias per million for Mexican and Salvadoran children with those 
for Hispanic children from three U.S. Cancer Registries and for children from Costa Rica
Leukemia 
type
SEER 2001 
All races (30)
Mexico City, 
IMSS
Texas (34) California 
(3)
SEER 1992–1998 
Hispanics (29)
El Salvador Florida (4) Costa Rica 
(5)
Lymphoid 
leukemia
33.2 44.9 52.0 44.0 43.0 34.2* 49.7 43.1
IMSS = Instituto Mexicano del Seguro Social.
* This rate is only for children 0–11 years old.
(References)BMC Cancer 2005, 5:33 http://www.biomedcentral.com/1471-2407/5/33
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which 36% of the cases with cancer were Hispanic chil-
dren, it was found that the use of "Propargite", a pesticide
used primarily in orchards and vineyards to control mites,
was related to the higher rates of childhood leukemia
[36].
The standardized incidence rate of ALL for children under
12 years of age in El Salvador was found to be less than the
AAIR reported for Costa Rica or for Florida, where the
highest percentage of Hispanics are of Caribbean and
Central American origin, but this rate is relatively higher
than that reported by SEER for all races [30]. This compar-
ison has to be taken with some reservation because the
AAIRs of SEER are reported for children under 15 years of
age, whereas that of El Salvador is for only those under 12
years of age.
The frequency of AML M3 in the Hispanic population has
been reported to be higher than those for other popula-
tions [37]. This has been observed both for children and
for adults [3,37-39] (Table 4). In the present study, it was
found that, in Mexico City, the frequency was 21%, a
value consistent with the data that the frequency of AML
M3 is higher in a population of Hispanic origin. The
present study has the advantage over other studies that
were carried out in Latin America because it is population-
based. One study has proposed that the elevated fre-
quency of AML in the Hispanic population may be related
not only genetic factors but also nutritional ones [38].
It is important to emphasize that, despite recent data pub-
lished on the incidence of leukemias in Latin America
[5,40] or in Hispanics from the USA [29], those study
periods were prior to those analyzed here. Finally, it can
be stated that the rates here presented are similar to those
reported for Latin America, thereby supporting the relia-
bility of these results. This is the start of a project that
intends to join efforts in Mexico City, El Salvador,
Honduras, Guatemala, Costa Rica, and Nicaragua to keep
records of cancer in children, which will be highly reliable
and which, therefore, can provide valid and timely data
on the great concern that child cancer represents in the
Latin American countries.
Conclusion
The AAIRs reported for Mexico City and the rate in chil-
dren from 0–11 years old in El Salvador were similar to
those that have been reported by other Latin American
countries. The AAIR of ALL in Mexico City is one of the
highest in the world.
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Table 4: Comparison of the proportion of promyelocytic leukemias for Mexican children with Hispanic children from other countries 
and cities.
Adults Children
Leukemia 
type
LAC-USC 
(37)
LA County 
and AML 
study (37)
Peru (38) Puebla, 
Mexico (39)
California* 
(3)
Puebla, 
Mexico (39)
Mexico City, 
IMSS
Range in non-
Hispanic 
populations** (37)
Promyelocytic 
leukemia
37.5% 24.3% 22.0% 20.0% 8.3% 30.0% 21.0% 3–13%
LAC-USC = Los Angeles County-University of Southern California; LA: Los Angeles; AML = acute myeloid leukemia; IMSS = Instituto Mexicano del 
Seguro Social.
* This is a population-based study in which a frequency of 3.8%was found for non-Hispanic children.
** This range is based on proportions found in series of cases.
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